Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer.
Two different injectable drugs can lower cholesterol levels even further than statins do, potentially warding off future heart attacks or strokes, new research suggests.